北京医学
北京醫學
북경의학
BEIJING MEDICAL JOURNAL
2015年
4期
381-383
,共3页
张烨%王颖%闫芳%张磊%刘素芳%许志远
張燁%王穎%閆芳%張磊%劉素芳%許誌遠
장엽%왕영%염방%장뢰%류소방%허지원
PCR-SSP%部分D%RhD外显子%DⅥⅢ型
PCR-SSP%部分D%RhD外顯子%DⅥⅢ型
PCR-SSP%부분D%RhD외현자%DⅥⅢ형
PCR-SSP%Partial D%RhD exons%DⅥtypeⅢ
目的:探讨血清学定型为RhD变异型DⅥⅢ型的分子基础。方法对2例RhD定型弱阳性、阴性反应的标本进行ABD(DⅥ-)血型卡检测、试管法检测IgM抗-D、Liss/Coombs卡检测IgG抗-D、直接抗人球蛋白试验、Rh分型卡检测Rh抗原分型、同时采用PCR-SSP进行RhD基因检测。结果2例标本IgM抗-D均阴性,3批IgG抗-D均4+,ABD(DⅥ-)血型卡D阴性,Rh分型为Ccee,RhD基因检测结果为D3-6外显子缺失,确认为DⅥⅢ型,基因结构为RhD-CE(3-6)-D。结论对于RhD弱阳性的标本可采用分子生物学的方法做基因定型。作为受血者和供血者在临床输血中和临床抗-D同种免疫的预防和监护中的策略是不同的。
目的:探討血清學定型為RhD變異型DⅥⅢ型的分子基礎。方法對2例RhD定型弱暘性、陰性反應的標本進行ABD(DⅥ-)血型卡檢測、試管法檢測IgM抗-D、Liss/Coombs卡檢測IgG抗-D、直接抗人毬蛋白試驗、Rh分型卡檢測Rh抗原分型、同時採用PCR-SSP進行RhD基因檢測。結果2例標本IgM抗-D均陰性,3批IgG抗-D均4+,ABD(DⅥ-)血型卡D陰性,Rh分型為Ccee,RhD基因檢測結果為D3-6外顯子缺失,確認為DⅥⅢ型,基因結構為RhD-CE(3-6)-D。結論對于RhD弱暘性的標本可採用分子生物學的方法做基因定型。作為受血者和供血者在臨床輸血中和臨床抗-D同種免疫的預防和鑑護中的策略是不同的。
목적:탐토혈청학정형위RhD변이형DⅥⅢ형적분자기출。방법대2례RhD정형약양성、음성반응적표본진행ABD(DⅥ-)혈형잡검측、시관법검측IgM항-D、Liss/Coombs잡검측IgG항-D、직접항인구단백시험、Rh분형잡검측Rh항원분형、동시채용PCR-SSP진행RhD기인검측。결과2례표본IgM항-D균음성,3비IgG항-D균4+,ABD(DⅥ-)혈형잡D음성,Rh분형위Ccee,RhD기인검측결과위D3-6외현자결실,학인위DⅥⅢ형,기인결구위RhD-CE(3-6)-D。결론대우RhD약양성적표본가채용분자생물학적방법주기인정형。작위수혈자화공혈자재림상수혈중화림상항-D동충면역적예방화감호중적책략시불동적。
Objective To genotype weak D phenotype and study the molecular background of DⅥtypeⅢ. Meth?ods The RhD blood type of two blood samples were typed by tube test with IgM anti-D, Liss/Coombs card with IgG anti-D,ABD(DⅥ-)typing card .DAT and Rh phenotype were tested by gel card.The genotype of both samples were identified by PCR-SSP. Results The reactivity of the two samples were negative(one lot IgM anti-D),wesk positive (two lots Ig-Manti-D) , 4+(three lots IgG anti-D) and negative (anti-DⅥ-).Both Rh phenotype were Ccee.The two samples were de-tected negative in exons 3-6 of RhD gene. The RhD of both samples was identified DⅥtypeⅢ,Rh gene was RhD-CE(3-6)-D. Conclusion Genotype may be tested for weak D phenotype.The genotype of the two samples was DⅥtypeⅢ. We may still consider D VI phenotype individuals as D positive donors and D negative receiptions in our transfusion practice and in clinical anti D allo immune prophylaxis and monitoring.